DFDA

Benzathine Penicillin G

Treatment for Rheumatic Heart Disease

Typical Dosage: 1.2 million units IM every 3-4 weeks

Effectiveness
95%
Safety Score
70%
Clinical Trials
5
Participants
50K

Comparative Safety Scale(Higher is safer)

Cyanide☠ī¸
Meth💀
CigarettesđŸšŦ
Chemoâ˜ĸī¸
AlcoholđŸē
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
1.2 million units IM every 3-4 weeks
Time to Effect
immediate
Treatment Duration
lifetime (or long-term)
Evidence Quality
HIGH
Number Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
2000(Treat 2000 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$450
Side Effect Mgmt:$50
Total Annual:$700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$4,000/QALY
QALYs Gained
2
Outcome-Based Costs
Cost per Responder
$737
Comparison vs No prophylaxis
Cost Difference
+$700/year
More expensive
QALY Difference
+2.00 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Risk Assessment
Requires Monitoring
Yes
Needs lab work/checkups
Benzathine Penicillin G Outcomes

for Rheumatic Heart Disease

Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+95%
Common Side Effects
Injection site pain
+20%
Mild allergic reaction (rash)
+5%
Anaphylaxis
+0.1%

Sources:

rhdaction.org
aihw.gov.au
sci-rep.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
3 active trials recruiting for Benzathine Penicillin G in Rheumatic Heart Disease

GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial

NCT05693545ACTIVE NOT RECRUITINGPHASE2
View Study
1K participants
INTERVENTIONAL
Kampala, Uganda
Started: Sep 1, 2023

Improving Management and Secondary Prevention Through Azithromycin Comparative Trial in Rheumatic Heart Disease in Nigeria)- IMPACT-RHD Nigeria

NCT07625228NOT YET RECRUITINGNA
View Study
474 participants
INTERVENTIONAL
Started: Jan 5, 2027

A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop

NCT07146048RECRUITINGPHASE3
View Study
922 participants
INTERVENTIONAL
Kampala, Uganda
Started: Mar 23, 2026
Completed Clinical Trials
2 completed trials for Benzathine Penicillin G in Rheumatic Heart Disease

A Long-term Follow up Study for Patients Who Participated in the GOAL Trial (GOAL-Post)

NCT05211024COMPLETED
View Study
1.42K participants
OBSERVATIONAL
Kampala, Uganda
Started: Jan 28, 2022

Case Management and Peer Support Groups for Prophylaxis Adherence in Rheumatic Heart Disease

NCT05502042COMPLETEDNA
View Study
209 participants
INTERVENTIONAL
Tororo, Uganda
Started: Aug 15, 2022